Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-166-5 | CAS number: 12108-13-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
Description of key information
Additional information
Two in vitro and two in vivo studies providing information on the effects of Mn (iin the form of mmt) are included
In vitro
Anantharam (2002)
The oxidative stress-dependent cellular events in dopaminergic cells after exposure to a mmt In pheochromocytoma cells was characterizzed. mmt exposure resulted in rapid increase in generation of reactive oxygen species (ROS) within 5 -15 min, followed by release mitochondrial cytochrome C into cytoplasm and subsequent activation of cysteine proteases, caspase-9 (two-fold to three-fold), and caspase-3 (15- to 25- fold), but not caspase-8, in a time- and dose-dependent manner. mmt exposure induces a time- and dose-dependent porteolytic cleavage of native protein kinase Cδ (PKCδ, 72 -74 kDa) to yield 41 kDa catalytically active and 38 kDa regulatory fragments. Pretreatment with caspase inhibitors (Z-DEVD-FMK or Z-VAD-FMK) blocked mmt-induced proteolytic cleavage of PKCδ, indicating that cleavage is mediated by caspase-3. Furthermore, inhibition of PKCδ activity with a specific inhibitor, rottlerin, significantly inhibited caspase-3 activation in a dose-dependent manner along with a reduction in PKCδ cleavage products, indicating a possible positive feedback activation of caspase-3 activity by PKCδ. The presence of such a positive feedback loop was also confirmed by delivering the catalytically active PKCδ fragment. Attenuation of ROS generation, caspase-3 activation, and PKCδ activity before mmt treatment almost completely suppressed DNA fragmentation. Additionally, overexpression of catalytically inactive PKCδ^K376R (dominant negative mutant) prevented mmt-induced apoptosis in immortalized mesencephalic dopaminergic cells. These data demonstrate that caspase-3 -dependent proteolytic activation of PKCδ plays a key role in oxidative stress-mediated apoptosis in dopaminergic cells after exposure to mmt.
Kitazawa (2002)
mmt was investigated to determine whether it potentially causes dopaminergic neurotoxic effects. mmt is acutely cytotoxic with dopamine-producing cells (PC-12) seemed to be more susceptible to cytotoxic effects than nondopaminergic cells (striatal γ-aminobutyric acidergic and cerebellar granule cells). mmt also potently depleted dopamine apparently by cytoplasmic vesicular release to the cytosol, a neurochemical change resembling other dopaminergic neutoxicants. Generation of reactive oxygen species (ROS), an early effect in toxicant-induced apoptosis, occurred within 15 minutes of mmt-exposure. mmt caused a loss of mitochondrial transmembrane potential (∆ψm), a likely source of ROS generation. The ROS signal further activated caspase-3, an important effector caspase, which could be inhibited by antioxidants (Trolox or N-acetylcysteine). Predepletion, of dopamine by using α-methyl-ρ-tyrosine (tyrosine hydroxylase inhibitor) treatment partially prevented caspase-3 activation, denoting a significant dopamine and/or dopamine by-product contribution to initiation of apoptosis. Genomic DNA fragmentation, a terminal hallmark of apoptosis, was induced concentration dependently by mmt but completely prevented by pretreatment with Trolox, deprenyl (monoamine oxidase-B inhibitor) and α-methyl-ρ-tyrosine. A final set of critical experiments was performed to verify the pharmacological studies using a stable Bcl-2-overexpressing PC-12 cell line. Bcl-2-overexpressing cells were significantly refractory to mmt-induced ROS generation, caspase-3 activation, and loss of ∆ψm and were completely resistant to MMT-induced DNA fragmentation. Taken together, the results presented herein demonstrate that oxidative stress plays an important role in mitochondrial-mediated apoptotic cell death in cultured dopamine-producing cells after exposure to mmt.
In vivo
Liu (1999)
The in vivo effect of mmt was studied on the motor nerve of the mouse. Adult mice of the ICR strain, weighing 25 -30g were pretreated intraperitoneally with mmt in corn oil (0.05 and 0.01 mg/g/day for 3 days). The motor nerve conduction velocity was markedly decreased in mmt-treated mice. The Na+, K+-ATPase activity of sciatic nerve isolated from mmt-treated mice was decreased; however, the sciatic nerve Na+, K+-ATPase activity was not affected by the in vitro treatment of mmt. Moreover, [3H]ouabain binding of sciatic nerve isolated from mmt-treated mice was decreased. Using Western blot analysis, the amount of Na+, K+-ATPase catalytic α1 subunit polypeptide in sciatic nerve of mmt-treated mice was also decreased. These results indicate that a causal relationship may exist between reduced nerve Na+, K+-ATPase activity and motor nerve conduction velocity in mmt-treated mice and that a measurable decrease in α1 catalytic subunit isoform of Na+, K+-ATPase may be necessary for the development of peripheral neuropathy by mmt.
Gianatsus (1985)
Mice received an acute sc dose of manganese chloride, oxide (Mn3O4) or mmt (0.2 or 0.4meq/kg). A single injection markedly elevated brain manganese concentrations within 1 day with elevated levels maintained for at least 21 days. Repeated injections led to further increases in both brain and blood, although the levels in the brain appeared to persist at consistently high levels for longer periods. The chloride form produced higher brain levels than either of the other two forms. These results appear to suggest that the slowly developing neurotoxicity in response to manganese exposure may be due to a persistent retention of manganese by the brain. The oxide was chosen because is the combustion product of mmt, while the dichloride form is a water soluble salt of the metal.
Both brain and blood manganese levels were elevated after injection, but there was a slight difference in the time course of this effect between the two tissues. There was also a difference dependent on the form of Mn tested. With the oxide form, blood manganese reached a maximum 4h after injection and remained elevated after 1 week. In the brain, Mn reached is peak at 24h after administration, remained also constant for 1 week. With the dichloride form, peak blood levels reached extremely high values (more than 10 000% of control) within 1h and gradually declined over the course of 1 week (although they were still 740% of control at 1 week). In the brain peak levels occurred approximately 24h after injection and remained at this level for at least 1 week.
A similar trend was observed with repeated injections. Higher brain and blood levels of Mn were detected with repeated injections of either compound than following an acute injection. However, the elevated brain Mn levels appeared to be less readily reversible than the blood; brain levels 21 days after a single injection of either form of Mn were no different from the levels observed 7 days after a single injection. Blood levels, although still significantly elevated above the control by 21 days, had significantly declined compared with values obtained 1 week after injection. Thus, the exit of Mn from the brain, appears to be a slower process than the entry of the metal.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.